Narumi Nakagiri
Stock Analyst at Daiwa Capital
(0.94)
# 2,791
Out of 4,424 analysts
6
Total ratings
66.67%
Success rate
-3.11%
Average return
Main Sectors:
Top Industries:
4 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Upgrades: Buy | $320 | $310.15 | +3.18% | 2 | Dec 21, 2023 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $54 | $44.94 | +20.16% | 1 | Nov 2, 2023 | |
| PFE Pfizer | Downgrades: Neutral | $38 | $28.01 | +35.67% | 2 | May 11, 2023 | |
| MRK Merck & Co. | Upgrades: Outperform | $89 → $102 | $130.06 | -21.57% | 1 | Jul 7, 2022 |
Amgen
Dec 21, 2023
Upgrades: Buy
Price Target: $320
Current: $310.15
Upside: +3.18%
Bristol-Myers Squibb Company
Nov 2, 2023
Downgrades: Neutral
Price Target: $68 → $54
Current: $44.94
Upside: +20.16%
Pfizer
May 11, 2023
Downgrades: Neutral
Price Target: $38
Current: $28.01
Upside: +35.67%
Merck & Co.
Jul 7, 2022
Upgrades: Outperform
Price Target: $89 → $102
Current: $130.06
Upside: -21.57%